Initiation of Guideline-Matched Oral Anticoagulant in Atrial Fibrillation-Related Stroke
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose: To evaluate the outcome events and bleeding complications of the European Society of Cardiology (ESC) guideline-matched oral anticoagulant therapy for patients with acute ischemic stroke and atrial fibrillation (AF). Methods: Patients with acute ischemic stroke and AF from a nationwide multicenter registry(Korean ATrial fibrillaTion EvaluatioN regisTry in Ischemic strOke patieNts [K-ATTENTION]) between January 2013 and December 2015 were included in the study. Patients were divided into the ESC guideline- matched and the non-matched groups. The primary outcome was recurrence of any stroke during the 90-day follow-up period. Secondary outcomes were major adverse cerebrovascular and cardiovascular events, ischemic stroke, intracranial hemorrhage, acute coronary syndrome, allcause mortality, and major hemorrhage. Propensity score matching and logistic regression analyses were performed to assess the effect of the treatments administered. Results: Among 2,321 eligible patients, 1,126 patients were 1:1 matched to the ESC guidelinematched and the non-matched groups. As compared with the non-matched group, the ESC guideline- matched group had a lower risk of any recurrent stroke (1.4% vs. 3.4%; odds ratio[OR], 0.41; 95% confidence interval [CI], 0.18 to 0.95). The risk of recurrent ischemic stroke was lower in the ESC guideline-matched group than in the non-matched group (0.9% vs. 2.7%; OR, 0.32; 95% CI, 0.11 to 0.88). There was no significant difference in the other secondary outcomes between the two groups. Conclusions: ESC guideline-matched oral anticoagulant therapy was associated with reduced risks of any stroke and ischemic stroke as compared with the non-matched therapy.
Abstract
Background and Purpose: To evaluate the outcome events and bleeding complications of the European Society of Cardiology (ESC) guideline-matched oral anticoagulant therapy for patients with acute ischemic stroke and atrial fibrillation (AF). Methods: Patients with acute ischemic stroke and AF from a nationwide multicenter registry(Korean ATrial fibrillaTion EvaluatioN regisTry in Ischemic strOke patieNts [K-ATTENTION]) between January 2013 and December 2015 were included in the study. Patients were divided into the ESC guideline- matched and the non-matched groups. The primary outcome was recurrence of any stroke during the 90-day follow-up period. Secondary outcomes were major adverse cerebrovascular and cardiovascular events, ischemic stroke, intracranial hemorrhage, acute coronary syndrome, allcause mortality, and major hemorrhage. Propensity score matching and logistic regression analyses were performed to assess the effect of the treatments administered. Results: Among 2,321 eligible patients, 1,126 patients were 1:1 matched to the ESC guidelinematched and the non-matched groups. As compared with the non-matched group, the ESC guideline- matched group had a lower risk of any recurrent stroke (1.4% vs. 3.4%; odds ratio[OR], 0.41; 95% confidence interval [CI], 0.18 to 0.95). The risk of recurrent ischemic stroke was lower in the ESC guideline-matched group than in the non-matched group (0.9% vs. 2.7%; OR, 0.32; 95% CI, 0.11 to 0.88). There was no significant difference in the other secondary outcomes between the two groups. Conclusions: ESC guideline-matched oral anticoagulant therapy was associated with reduced risks of any stroke and ischemic stroke as compared with the non-matched therapy.
참고문헌 (25)
- Hart RG, "Meta-analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation", Ann Intern Med, 146, pp.857~867 (2007)
- Saxena R, "Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack", Cochrane Database Syst Rev, 4 (2004)
- Hart RG, "Early recurrent embolism associated with nonvalvular atrial fibrillation : a retrospective study", Stroke, 14, pp.688~693 (1983)
- D’Amelio M, "Early and late mortality of spontaneous hemorrhagic transformation of ischemic stroke", J Stroke Cerebrovasc Dis, 23, pp.649~654 (2014)
- Hong KS, "Rivaroxaban vs warfarin sodium in the ultra-early period after atrial fibrillation-related mild ischemic stroke : a randomized clinical trial", JAMA Neurol, 74, pp.1206~1215 (2017)
- Butcher KS, "Dabigatran treatment of acute noncardioembolic ischemic stroke", Stroke, 51, pp.1190~1198 (2020)
- Wilson D, "Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation : multicentre cohort study", J Neurol Neurosurg Psychiatry, 90, pp.320~325 (2019)
- Paciaroni M, "Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-k oral anticoagulants(RAF-NOACs)Study", J Am Heart Assoc, 6, pp.e007034~ (2017)
- January CT, "2014 AHA", ACC, American Heart Association Task Force on practice guidelines and the Heart Rhythm Society, pp.Circulation, 2014[DOI]
- Kirchhof P, "2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS", Eur Heart J, 37, pp.2893~2962 (2016)
- Ahmed N, "Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13-15 November 2016", Eur Stroke J, 2, pp.95~102 (2017)
- Song TJ, "Characteristics and factors for short-term functional outcome in stroke patients with atrial fibrillation, nationwide retrospective cohort study", Front Neurol, 10, pp.1101~ (2019)
- Parsons LS, "Performing a 1:N case-control match on propensity score", Proceedings of the 29th Annual SAS Users Group International Conference (2004), SAS Institute
- Seiffge DJ, "Early start of DOAC after ischemic stroke : risk of intracranial hemorrhage and recurrent events", Neurology, 87, pp.1856~1862 (2016)
- Seiffge DJ, "Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation", Ann Neurol, 85, pp.823~834 (2019)
- International Stroke Trial Collaborative Group, "The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke", Lancet, 349, pp.1569~1581 (1997)
- Freedman MD, "Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects", J Clin Pharmacol, 32, pp.196~209 (1992)
- Azoulay L, "Initiation of warfarin in patients with atrial fibrillation : early effects on ischaemic strokes", Eur Heart J, 35, pp.1881~1887 (2014)
- Alves HC, "Thrombus migration paradox in patients with acute ischemic stroke", Stroke, 50, pp.3156~3163 (2019)
- Gorog DA, "Arterial thrombus stability : does it matter and can we detect it", J Am Coll Cardiol, 70, pp.2036~2047 (2017)
- Corrado G, "Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation", Chest, 115, pp.140~143 (1999)
- Kaku B, "Intra-cardiac thrombus resolution after anti-coagulation therapy with dabigatran in a patient with midventricular obstructive hypertrophic cardiomyopathy : a case report", J Med Case Rep, 7, pp.238~ (2013)
- Manning WJ, "Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation", Arch Intern Med, 155, pp.2193~2198 (1995)
- Paciaroni M, "Hemorrhagic transformation in patients with acute ischemic stroke and atrial fibrillation : time to initiation of oral anticoagulant therapy and outcomes", J Am Heart Assoc, 7, pp.e010133~ (2018)
- Xian Y, "Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke : findings from the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research(PROSPER)Study", JAMA Neurol, 76, pp.1192~1202 (2019)